Significance of postoperative structural changes in serum N- glycans in pancreatic cancer patients
-
摘要: 目的研究胰腺癌患者血清特征性N-糖链结构变化规律,期望找到胰腺癌特异性血清标志物。方法选取2011年6月至2013年12月在哈尔滨医科大学附属第三医院就诊的胰腺癌患者,将检测对象分成胰腺癌患者术前血清组(123例)与术后血清组(78例)。选取体检中心收集的健康人群血清样本271例作为健康人血清组。应用基于DNA测序仪的荧光糖电泳(DSAFACE)技术比较分析3组血清中N-糖链的变化。计量资料以均数±标准差(x±s)表示,2组间比较采用成组t检验。结果通过对血清N-糖链的DSA-FACE分析,确定了胰腺癌患者血清N-糖链谱图,在此基础上比较分析胰腺癌患者术前、术后血清与健康人血清的N-糖链变化。糖峰8在胰腺癌患者术前组显著低于健康人群组(t=2.735,P<0.05)及术后组(P<0.05),而术后组与健康组差异无统计学意义。结论糖峰8可以成为辅助的胰腺癌诊断标志糖链。Abstract: Objective To investigate the structural changes in specific serum N- glycans in pancreatic cancer patients and to identify the specific serum maker of pancreatic cancer.Methods The pancreatic cancer patients who visited the Third Affiliated Hospital of Harbin Medical University from June 2011 to December 2013 were assigned to preoperative serum group (123 cases) and postoperative serum group (78 cases) ;healthy controls whose serum samples were collected in the Physical Examination Center were selected as control serum group (271 cases) .DNA sequencer- aided fluorophore- assisted carbohydrate electrophoresis (DSA- FACE) was used to analyze serum N-glycans and compare them between the three groups.Results The serum N- glycan profiles in pancreatic cancer patients were identified by DSA- FACE.The results indicated that N- glycan peak 8 in preoperative serum group was significantly lower than those in control serum group (t = 2.735, P < 0.05) and postoperative serum group (P < 0.05) , but no significant difference was found between the postoperative serum group and control serum group.Conclusion N- glycan peak 8 can be considered as a serum marker of pancreatic cancer.
-
Key words:
- pancreatic neoplasms /
- DSA-FACE, N-Glycans /
-
[1]Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association.Guidelines for the management of pancreatic cancer[J].Chin J Pract Surg, 2007, 27 (9) :671-673. (in Chinese) 中华医学会外科学分会胰腺外科学组.胰腺癌诊治指南[J].中国实用外科杂志, 2007, 27 (9) :671-673. [2]LI ZS.Status and prospects of early diagnosis of pancreatic cancer[J].J Clin Hepatol, 2010, 26 (5) :451-458. (in Chinese) 李兆申.胰腺癌早期诊断研究现状及展望[J].临床肝胆病杂志, 2010, 26 (5) :451-458. [3]JEMAL A, SIEGEL R, WARD E, et al.Cancer Statistics, 2009[J].CA Cancer J Clin, 2009, 59 (4) :225-249. [4]CALLEWAERT N, GEYSENS S, MOLEMANS F, et al.Ultrasensitive profiling and sequencing of N-linked oligosaccharides using standard DNA-sequencing equipment[J].Glycobiology, 2001, 11 (4) :275-281. [5]CHEN C, SCHMILOVITZ-WEISS H, LIU XE, et al.Serum protein N-Glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis[J].J Proteome Res, 2009, 8 (2) :463-470. [6]LIU XE, DESMYTER L, GAO CF, et al.N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus[J].Hepatology, 2007, 46 (5) :1426-1435. [7]GENG F, WU XZ.Research advances inα-1, 6-fucosyltransferase[J].Chem Life, 2003, 23 (2) :118-120. (in Chinese) 耿飞, 吴兴中.α-1, 6岩藻糖基转移酶的研究进展[J].生命的化学, 2003, 23 (2) :118-120. [8]CUI W, XU XH.Clinical value of combined measurement of serumCA19-9, CA242, CEA, and LAP in diagnosis of pancreatic cancer[J].J Radioimmunol, 2011, 24 (3) :353-355. (in Chinese) 崔巍, 徐笑红.血清CA19-9、CA242、CEA、LAP联检诊断胰腺癌的临床价值[J].放射免疫学杂志, 2011, 24 (3) :353-355. [9]CHEN D, FAN YH.Clinical value and limitations of serum CA19-9 as a biomarker of pancreatic cancer[J].J Clin Hepatol, 2013, 29 (3) :239-240. (in Chinese) 陈达, 樊艳华.CA19-9在胰腺癌中的应用价值及局限性[J].临床肝胆病杂志, 2013, 29 (3) :239-240. [10]GUO XZ.Progress in medical diagnosis and treatment of pancreatic cancer[J].Chin J Pancreatol, 2013, 13 (3) :145-146. (in Chinese) 郭晓钟.胰腺癌内科诊治进展[J].中华胰腺病杂志, 2013, 13 (3) :145-146.
本文二维码
计量
- 文章访问数: 2731
- HTML全文浏览量: 10
- PDF下载量: 552
- 被引次数: 0